'Stealth' corporate innovation: an emerging threat for therapeutic drug development
Publication date
2019-11
Authors
Mastellos, Dimitrios C
Blom, Anna M
Connolly, E Sander
Daha, Mohamed R
Geisbrecht, Brian V
Ghebrehiwet, Berhane
Gros, Piet
Hajishengallis, George
Holers, V Michael
Huber-Lang, Markus
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Taverne
Citation
Mastellos, D C, Blom, A M, Connolly, E S, Daha, M R, Geisbrecht, B V, Ghebrehiwet, B, Gros, P, Hajishengallis, G, Holers, V M, Huber-Lang, M, Kinoshita, T, Mollnes, T E, Montgomery, R A, Morgan, B P, Nilsson, B, Pio, R, Ricklin, D, Risitano, A M, Taylor, R P, Mantovani, A, Ioannidis, J P A & Lambris, J D 2019, ''Stealth' corporate innovation : an emerging threat for therapeutic drug development', Nature Immunology, vol. 20, no. 11, pp. 1409-1413. https://doi.org/10.1038/s41590-019-0503-1